CN114460190A - 一种β2-微球蛋白含量测定方法 - Google Patents
一种β2-微球蛋白含量测定方法 Download PDFInfo
- Publication number
- CN114460190A CN114460190A CN202210057989.4A CN202210057989A CN114460190A CN 114460190 A CN114460190 A CN 114460190A CN 202210057989 A CN202210057989 A CN 202210057989A CN 114460190 A CN114460190 A CN 114460190A
- Authority
- CN
- China
- Prior art keywords
- beta
- microglobulin
- measuring
- solution
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015736 beta 2-Microglobulin Human genes 0.000 title claims abstract description 39
- 108010081355 beta 2-Microglobulin Proteins 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000243 solution Substances 0.000 claims abstract description 28
- 239000013558 reference substance Substances 0.000 claims abstract description 20
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004202 carbamide Substances 0.000 claims abstract description 12
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 10
- 239000012088 reference solution Substances 0.000 claims abstract description 8
- 239000012085 test solution Substances 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000001514 detection method Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 claims description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 claims description 2
- 238000010812 external standard method Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 abstract description 4
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Library & Information Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种β2‑微球蛋白含量测定方法，步骤一：制备供试品溶液；取样品1ml，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，用0.45μm滤膜过滤，即得；步骤二：制备对照品溶液；取β2‑微球蛋白对照品适量，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，制得的溶液中每1ml含β2‑微球蛋白10μg；步骤三：按照高效液相色谱法测定；本发明采用高效液相色谱法进行测定，可以快速便捷的测定患者的尿液和腹膜透出液中β2‑微球蛋白结果，对于监测患者体内β2‑微球蛋白具有重要意义，同时对于人工肾研发具有重要意义。
Description
技术领域
本发明属于医药技术领域，具体涉及一种β2-微球蛋白含量测定方法。
背景技术
β2-微球蛋白(β2-MG)是人类白细胞抗原(HLA)Ⅰ类抗原的轻链，是由淋巴细胞、血小板、多形核白细胞产生的一种低分子量血清球蛋白，存在于成熟红细胞和胎盘滋养层细胞外的各种细胞表面。β2-微球蛋白极易通过肾小球滤过膜，几乎全部被近曲小管细胞重吸收和降解，不再回流入血。健康人β2-微球蛋白的合成速度和细胞膜释放量非常恒定，故体内β2-微球蛋白保持稳定。
检测血或尿中的β2-MG浓度为临床肾功能测定、肾移植成活、糖尿病肾病、重金属镉、汞中毒、某些恶性肿瘤、病毒感染、自身免疫性疾病的临床诊断提供较早、可靠和灵敏的指标，同时也为鉴别蛋白尿性质、肾小球或肾小管病变、尿路感染部位等提供依据。唾液中β2-微球蛋白检测可为诊断干燥综合征及某些口腔疾病提供依据，干燥综合征患者血清和唾液β2微球蛋白含量明显升高，且唾液β2微球蛋白含量较血清中的高。
目前β2-微球蛋白的检测方法，均为免疫法，包括放射免疫分析法、酶联免疫吸附法、时间分辨荧光免疫分析法、免疫透射法、免疫散射比浊法、胶乳免疫散射比浊法、乳胶增强免疫比浊法等，其试剂盒需要使用配套型号的全自助生化分析仪，局限性较强，现急需一种可使用通用仪器进行检测的方法。
本发明中提供了一种高效液相法实现了对β2-微球蛋白的检测，可采用本发明中的方法对尿毒症患者的尿液及腹膜透析患者的透出液进行测定。
发明内容
本发明的目的在于提供一种β2-微球蛋白含量测定方法，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：一种β2-微球蛋白含量测定方法，步骤一：制备供试品溶液；取样品1ml，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，用0.45μm滤膜过滤，即得；
步骤二：制备对照品溶液；取β2-微球蛋白对照品适量，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，制得的溶液中每1ml含β2-微球蛋白10μg；
步骤三：按照高效液相色谱法测定，精密量取供试品溶液和对照品溶液，分别注入液相色谱仪，记录色谱图，按外标法计算供试品溶液中β2-微球蛋白含量。
优选的，高效液相色谱法测定的色谱条件为：用十八烷基硅烷键合硅胶为填充剂；流动相：A相：0.1％三氟乙酸-水，B相：0.09％三氟乙酸-乙腈(A:B＝65～85:35～15)；检测波长为210～230nm；流速为每分钟0.5～1.0ml；柱温为40～55℃。
优选的，系统适用性为取对照品溶液进样，主峰的理论塔板数应大于2000。
优选的，步骤一和步骤二中进行室温放置时，需要保持量瓶密封。
优选的，所述高效液相色谱法测定中，进样体积为20μl。
与现有技术相比，本发明的有益效果是：本发明采用高效液相色谱法进行测定，可以快速便捷的测定患者的尿液和腹膜透出液中β2-微球蛋白结果，对于监测患者体内β2-微球蛋白具有重要意义，同时对于人工肾研发具有重要意义。
附图说明
图1为本发明的对照品溶液图谱示意图。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明方法主要的研究过程如下：
系统适用性
对照品溶液：取β2-微球蛋白对照品适量，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，制得的溶液中每1ml含β2-微球蛋白10μg。
取对照品溶液进样，结果表明，β2-微球蛋白色谱峰，峰型对称，理论塔板数大于2000。
专属性
对照品溶液：取β2-微球蛋白对照品适量，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，制得的溶液中每1ml含β2-微球蛋白10μg。
尿素溶液：取6mol/L尿素溶液，即得。
小分子毒素混合溶液：取乳酸钠对照品、肌酸对照品、尿酸对照品、肌酐对照品、苯乙酸对照品、马尿酸对照品、5-羟甲基糠醛对照品、3-吲哚乙酸对照品、对甲苯酚对照品各适量，加流动相溶解并定量稀释制成每1ml中约含乳酸钠400μg、肌酸4μg、尿酸20μg、肌酐4μg、苯乙酸20μg、马尿酸20μg、5-羟甲基糠醛20μg、3-吲哚乙酸20μg、对甲苯酚10μg的溶液。
取上述三种溶液分别进样，结果表明，尿素溶液和小分子毒素混合溶液，在本色谱条件下均不出峰，不干扰β2-微球蛋白的检测。
重复性
配制对照品溶液6份，分别进样，结果见下表。
由上表可知，6次结果的重复性良好。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (5)
1.一种β2-微球蛋白含量测定方法，其特征在于：步骤一：制备供试品溶液；取样品1ml，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，用0.45μm滤膜过滤，即得；
步骤二：制备对照品溶液；取β2-微球蛋白对照品适量，置100ml量瓶中，加入6mol/L尿素溶液至刻度，室温放置1小时后，制得的溶液中每1ml含β2-微球蛋白10μg；
步骤三：按照高效液相色谱法测定，精密量取供试品溶液和对照品溶液，分别注入液相色谱仪，记录色谱图，按外标法计算供试品溶液中β2-微球蛋白含量。
2.根据权利要求1所述的一种β2-微球蛋白含量测定方法，其特征在于：高效液相色谱法测定的色谱条件为：用十八烷基硅烷键合硅胶为填充剂；流动相：A相：0.1％三氟乙酸-水，B相：0.09％三氟乙酸-乙腈(A:B＝65～85:35～15)；检测波长为210～230nm；流速为每分钟0.5～1.0ml；柱温为40～55℃。
3.根据权利要求1所述的一种β2-微球蛋白含量测定方法，其特征在于：系统适用性为取对照品溶液进样，主峰的理论塔板数应大于2000。
4.根据权利要求1所述的一种β2-微球蛋白含量测定方法，其特征在于：步骤一和步骤二中进行室温放置时，需要保持量瓶密封。
5.根据权利要求1所述的一种β2-微球蛋白含量测定方法，其特征在于：所述高效液相色谱法测定中，进样体积为20μl。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210057989.4A CN114460190A (zh) | 2022-01-19 | 2022-01-19 | 一种β2-微球蛋白含量测定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210057989.4A CN114460190A (zh) | 2022-01-19 | 2022-01-19 | 一种β2-微球蛋白含量测定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114460190A true CN114460190A (zh) | 2022-05-10 |
Family
ID=81409772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210057989.4A Pending CN114460190A (zh) | 2022-01-19 | 2022-01-19 | 一种β2-微球蛋白含量测定方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114460190A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114854695A (zh) * | 2022-05-24 | 2022-08-05 | 广州蕊特生物科技有限公司 | 提高β-2微球蛋白在HEK-293细胞中表达水平的细胞转染培养方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101201360A (zh) * | 2006-12-15 | 2008-06-18 | 许洋 | 一种新型检测重型乙型肝炎的质谱分析试剂盒和方法 |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN112345671A (zh) * | 2020-12-14 | 2021-02-09 | 西安乐析医疗科技有限公司 | 一种乳酸盐型腹膜透析液中丙酮酸盐的测定方法 |
| CN113740464A (zh) * | 2021-09-23 | 2021-12-03 | 西安乐析医疗科技有限公司 | 一种苹果酸溶液中草酰乙酸含量的检测方法 |
-
2022
- 2022-01-19 CN CN202210057989.4A patent/CN114460190A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101201360A (zh) * | 2006-12-15 | 2008-06-18 | 许洋 | 一种新型检测重型乙型肝炎的质谱分析试剂盒和方法 |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN112345671A (zh) * | 2020-12-14 | 2021-02-09 | 西安乐析医疗科技有限公司 | 一种乳酸盐型腹膜透析液中丙酮酸盐的测定方法 |
| CN113740464A (zh) * | 2021-09-23 | 2021-12-03 | 西安乐析医疗科技有限公司 | 一种苹果酸溶液中草酰乙酸含量的检测方法 |
Non-Patent Citations (3)
| Title |
|---|
| SHIVA KALANTARI 等: "Urinary Prognostic Biomarkers and Classification of IgA Nephropathy by High Resolution Mass Spectrometry Coupled with Liquid Chromatography", PLOS ONE, vol. 8, no. 12, 5 December 2013 (2013-12-05), pages 80830 * |
| XIAZI QIU 等: "Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography–Multiple Reaction Monitoring–based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models", DRUG METABOLISM AND DISPOSITION, 31 October 2020 (2020-10-31), pages 925 - 933 * |
| 暴晓博 等: "基于凝胶过滤色谱的β2 微球蛋白标准品单体定量检测方法", 色谱, vol. 37, no. 5, 31 May 2019 (2019-05-31), pages 533 - 538 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114854695A (zh) * | 2022-05-24 | 2022-08-05 | 广州蕊特生物科技有限公司 | 提高β-2微球蛋白在HEK-293细胞中表达水平的细胞转染培养方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hamilton et al. | Comparison of the Fick and dye injection methods of measuring the cardiac output in man | |
| Morris et al. | Variables associated with radioimmunoassay of prostaglandins in plasma | |
| AU553993B2 (en) | Monitoring metabolic control in diabetic patients by measuring glycosylated amino acid and peptides in urine | |
| Heard et al. | The action of lower aldehydes on the human erythrocyte | |
| Elson | Quantitative determination of serum haptoglobin: a simple and rapid method | |
| CN114460190A (zh) | 一种β2-微球蛋白含量测定方法 | |
| CN205539004U (zh) | 一种检测ngal和糖化血红蛋白的检测试纸 | |
| CN204422546U (zh) | 肾损伤五合一检测卡 | |
| JACOBSON et al. | Urine osmolality: a definitive test of renal function | |
| CN112305207B (zh) | 基于HbA1c和血糖浓度为传感变量的红细胞平均寿命检测方法 | |
| Scott et al. | Effects of azotemia on results of the boronate-agarose affinity and ion-exchange methods for glycated hemoglobin. | |
| Viau et al. | Determination of rat β2‐microglobulin in urine and in serum. I. Development of an immunoassay based on latex particles agglutination | |
| CN110632217B (zh) | 一种hplc-icp-ms法测定粒细胞中四种砷化合物浓度的方法及应用 | |
| Horak et al. | Measurements of serum urea nitrogen by conductivimetric urease assay | |
| CN201600371U (zh) | β2-微球蛋白检测试剂盒 | |
| CN114674781A (zh) | 一种基于无创血糖仪准确性的判定装置及判定方法 | |
| AU746130B2 (en) | Measurement of plasma volume | |
| CN207717790U (zh) | 一种基于固相法快速血型鉴定的检测板 | |
| CN209878785U (zh) | 降钙素原检测试剂盒 | |
| CN115792003A (zh) | 一种测定甲基胍和胍基琥珀酸含量的方法 | |
| CN212904938U (zh) | 一种尿转铁蛋白快速检测装置 | |
| CN113686996B (zh) | 一种hplc测定血浆中腐植酸钠检测方法 | |
| CN219391938U (zh) | 一种全自动双通道糖化血红蛋白分析仪 | |
| CN103424552A (zh) | 一种检测人糖化白蛋白的测试卡 | |
| Kim | Proteinuria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |